Background: Recurrent pain events or chronic pain are among the most common complications of sickle cell disease. Despite attempts to maximize adherence to and dosing of hydroxyurea, some patients continue to suffer from pain. Our institution developed a program to initiate chronic red blood cell transfusions for one year in patients clinically deemed to have high healthcare utilization from sickle cell pain, despite being prescribed hydroxyurea.
guided imagery, and catastrophizing management. [7] [8] [9] However, the availability of resources to support these multidisciplinary approaches likely limits their widespread adoption. Chronic transfusion therapy offers another possible treatment for patients with frequent pain events. [10] [11] [12] [13] [14] [15] However, data investigating the effectiveness of this intervention for recurrent pain are limited. Current data for the effectiveness of transfusions in pediatrics are derived via secondary data analyses from clinical trials that initiated transfusion therapy for primary or secondary prevention of overt and/or silent stroke. Minimal data exist for the effectiveness of transfusion therapy in patients who initiated transfusions specifically for pain as the indication. To address this knowledge gap, we conducted a retrospective analysis of our institution's transfusion program for pain. We initiate chronic red blood cell transfusions for one year in patients clinically deemed to have high healthcare utilization from sickle cell pain, with minimal response to other therapies. We hypothesized that monthly red blood cell transfusion therapy for one year would reduce healthcare utilization for pain, decrease reliance on opioid prescriptions for pain management, and improve healthcare economics.
METHODS

Study population
We conducted an institutional review board-approved, retrospective study to evaluate the health outcomes associated with a one-year red blood cell transfusion protocol in sickle cell patients experiencing recurrent pain events as compared with the health outcomes for these patients in the one year prior to receiving transfusion therapy. We identified patients from 2012 to 2016 who received one year of transfusion therapy for an indication of recurrent pain in our University of Alabama at Birmingham Pediatric Sickle Cell clinical database. The decision to offer transfusion therapy to reduce frequent pain events was at the sole discretion of the attending physician. The decision to accept transfusion therapy relied on joint decision-making to incorporate family preferences and treatment burden. As patients with frequent pain events frequently accepted red blood cell transfusion therapy, we were unable to identify a control group of patients offered transfusion therapy for frequent pain but refused. All patients were scheduled to receive simple red blood cell transfusion every 4 weeks with a goal to maintain a percent sickle hemoglobin level between 30% and 50% and target a posttransfusion Hct of 32% and 34%. As standard of care, we perform minor antigen matching for all red cell transfusions in sickle cell patients. Hydroxyurea therapy could be continued during the one year of transfusion therapy based on joint decision-making between the physician and family.
Clinical investigation
Electronic medical records were reviewed to obtain data on health outcomes from one year prior to the initiation of transfusion therapy and one year post red blood cell transfusion therapy. Our primary outcome was to evaluate the impact of one-year blood cell transfusion therapy on emergency care utilization and hospitalizations for pain; data extracted included total number of clinic visits per year, emergency department (ED) visits (total visits and visits for pain crisis as the chief complaint), hospitalizations (total and pain crisis as the primary admission diagnosis), and total number of hospital days per admission.
We identified two patients with clinic notes documenting admission to an outside hospital for pain crisis, but we were unable to obtain medical records to confirm the number of hospital days. Therefore, we included the two hospital admissions in the total number of hospitalizations per year but excluded that admission from analysis of hospital days per admission. To evaluate alloimmunization, we extracted records for a positive antibody screen and subsequent identification of a specific antibody or nonspecific antibody by the Children's of Alabama blood bank. Ferritin levels from the 12-month visit and a liver iron content value estimated by T2* liver MRI within 3 months prior to or 6 months post their 12 month transfusion visit were recorded to document iron overload.
A secondary outcome was to evaluate the impact of chronic red cell transfusion on prescription opioid use. We used prescribed opioid quantity as a surrogate marker since we could not measure the actual quantity of opioid therapy used by the patient. We extracted data from the Alabama Prescription Drug Monitoring Program website on opioid prescription quantity and doses of opioids dispensed during the two-year study period. We calculated the oral morphine equivalents (OME) for each drug to be 0.15, 1, 4, 1, and 1.5 mg for codeine, hydrocodone, hydromorphone, morphine, and oxycodone, respectively, via the www.globalrph.com opioid analgesic converter.
The OME for three patients could not be determined, as data prior to November 2012 were not available on the Physician Drug Monitoring Program website.
Finally, we were interested in the health economics associated with a one-year transfusion protocol for patients with frequent pain events.
We imputed hospital costs using 2014-2015 claims data from the Alabama Children's Health Insurance Program, ALL Kids. ALL Kids contracts with Blue Cross/Blue Shield (BCBS) of Alabama (the single largest insurer in the state) for claims processing and access to BCBS provider networks and fee schedules. Based on inpatient claims data from 20 unique enrollees with one or more sickle cell pain hospitalizations (annual hospital days range, 1-30), the calculated average cost for one inpatient day was $2202. Next, we obtained cost from the outpatient clinic charges directly from the financial office at Children's of Alabama. We calculated the mean cost for a hydroxyurea clinic visit ($686/visit) and transfusion visit ($1505/visit) at Children's of Alabama. At our institution, the transfusion costs include performing extended phenotype matching and transfusing two units of packed red blood cells.
Statistical analysis
To describe the characteristics of these patients, we calculated counts and percentages for categorical variables and means, standard deviations, and ranges for continuous variables. To analyze the impact of transfusion to reduce ED visits, hospitalizations, hospitalization days, clinic visits, and OME prescribed, we performed a matched-pair analysis using a Wilcoxon signed-rank test to account for possible nonnormal distribution of data in this small study. JMP 13 (Cary, NC) was used for this analysis.
RESULTS
We identified 14 participants initiated on chronic transfusion therapy for one year to reduce frequent pain events. Eight patients (57%) were male. The mean age at initiation of transfusion therapy was 13.6 years. All patients were previously prescribed treatment with hydroxyurea before initiation of transfusion therapy. The mean hemoglobin 
DISCUSSION
Sickle cell patients with frequent pain events require multimodal interventions to improve their quality of life. These data suggest a chronic transfusion therapy protocol for patients with frequent pain can significantly reduce healthcare utilization among this high-risk population and improve healthcare economics. While this transfusion program significantly reduced the number of ED visits and hospitalizations for pain, this study did not identify that one year of transfusion therapy reduced the number of OME prescribed to each patient in one year.
One possible reason for failing to reduce opioid use is that patients who have transitioned to a chronic pain syndrome may continue to have pain despite reduction of their sickle hemoglobin. This suggests that pain may be driven by factors outside of the red blood cell and occur at the level of the peripheral and/or central nervous system and one year of chronic red cell transfusion therapy likely does not reverse this process. 16, 17 This concept is corroborated by data post bone marrow transplantation where patients continue to require opioid medications after this curative therapy. 18 A second possibility is that we used a surrogate marker of opioid prescription quantity filled rather than utilized. This finding may be relevant for patients with frequent pain who continued to request opioid prescriptions at each clinic visit for transfusion for management of their pain at home. Finally, while we did not capture school attendance and quality of life, based on prior literature we could hypothesize that both of these important patient-centered measures would improve during transfusion and are part of the joint therapeutic decision-making. 19 While transfusion therapy may improve healthcare utilization, obvi- These data suggest a clinical benefit to transfusion therapy for patients with recurrent pain crises; however, there are some limitations worth noting. First, we could not determine in this retrospective F I G U R E 1 Comparison of outcomes for 12 months prior to starting transfusion therapy and 12 months during transfusion therapy for (A) ED visits for pain in 12 months, (B) hospital admissions for pain in 12 months, (C) hospital days for pain in 12 months, (D) hospital days per admission for pain in 12 months, (E) total outpatient clinic visits in 12 months, and (F) OME prescribed in 12 months study the frequency of days with home pain or changes in the intensity of pain, which could provide additional data on the potential benefit of transfusion. Second, we did not obtain data on psychological comorbidities that contribute to frequent pain events including depression, anxiety, and poor sleep. In addition, we could not account for a positive relationship between frequent interactions with healthcare providers and a decrease in need for emergent healthcare utilization as patients were scheduled for transfusion every four weeks. Finally, we could not account for various out-of-pocket expenses for the costs of medications, clinic visits, or hospitalizations based on different insurance company policies, as well as the costs of travel to the clinic, childcare expenses, or missed days from work. For patients who continued on transfusion therapy after 12 months, several additional costs of healthcare to consider include the costs of chelation therapy, institutional iron overload monitoring, and potential costs for placing a central venous line and performing exchange transfusion therapy.
In conclusion, despite concerns for iron overload, infection, and alloimmunization inherent in a red blood cell transfusion protocol, patients with frequent pain episodes who are nonresponsive to hydroxyurea may benefit from one year of transfusion therapy. Future studies should include the impact of transfusion therapy on quality of life, missed school days, iron overload and alloimmunization to more fully assess the effects of transfusion on difficult to manage pain and determine the balance between benefit and risk.
